

Criteria-Based Consultation Prescribing Program

CRITERIA FOR DRUG COVERAGE

Budesonide (Tarpeyo)

Notes:

- Quantity Limits: No
- This is RESTRICTED DISTRIBUTION medication that is ordered through a non-Kaiser Specialty Pharmacy. This drug is not available at KP pharmacies.
- Adequate trial is determined by the prescribing nephrologist

Initiation (new start) criteria, Criteria for current Kaiser Permanente members already taking the medication who have not been reviewed previously, Criteria for new members entering Kaiser Permanente already taking the medication who have not been reviewed previously Non-formulary **budesonide (Tarpeyo)** will be covered on the prescription drug benefit for 12 months when the following criteria are met:

- Patient has a diagnosis of primary immunoglobulin A nephropathy (IgAN)
- The patient is 18 years of age or older
- The therapy is prescribed a nephrologist
- The patient's diagnosis is confirmed by a renal biopsy
- The patient is currently on an ACE inhibitor (e.g., benazepril, lisinopril) or an ARB (e.g., losartan, valsartan) at maximum tolerated dose for at least three months OR has a contraindication to both
- The patient has a progressively declining glomerular filtration rate (GFR) and/or worsening proteinuria (e.g., over 1 gram protein/24-hour urine collection or UPCR [urine protein to creatinine ratio] more than or equal to 1 g/g
- The patient had a trial of or contraindication to one generic systemic corticosteroid therapy (e.g., oral prednisone, oral prednisolone)
- Patient has tried and failed generic budesonide EC

Continued use criteria for patients previously approved per the above criteria who are currently stable on the medication: Continued use criteria for patients previously approved per the above criteria who are currently stable on the medication: Non-formulary **budesonide (Tarpeyo)** will continue to be covered on the prescription drug benefit for 12 months when the following criteria are met:

- The patient has improved, or stable kidney function compared to baseline
- The patient has had a reduction in proteinuria